References
- Chacon A, Franca K, Fernandez A, Nouri K. Psychosocial impact of onychomycosis: a review. Int J Dermatol. 2013;52:1300–7
- Gupta AK, Simpson FC. Laser therapy for onychomycosis. J Cutan Med Surg. 2013;17:301–7
- Heck R, Rossi C, Palma Kuhi I, Bakos L. Treatment of dermatophyte onychomycosis of the haluces with 1064 Nd:YAG laser. Surg Cosmet Dermatol. 2013;5:257–60
- Kalokasidis K, Onder M, Trakatelli M-G, et al. The effect of q-switched nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo. Dermatol Res Pract. 2013;2013:379725
- Waibel J, Rudnick A, Wulkan AJ. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol. 2013;12:1237–42
- Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;69:578–82
- Hollmig ST, Rahman Z, Henderson MT, et al. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014;70:911–17
- Gupta AK, Nakrieko K-A. Molecular determination of mixed infections of dermatophytes and nondermatophyte moulds in individuals with onychomycosis. J Am Podiatr Med Assoc. 2014;104:330--6
- Pinpointe USA. 510(k) Summary K093547. PinPointe FootLaser, Pinpointe USA Inc. [Internet]. FDA 510(k) Premarket Notification Database; 2010. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf. Accessed October 24, 2011
- Cutera Inc. 510(k) Summary K103626. GenesisPlus, Cutera Inc. [Internet]. FDA 510(k) Premarket Notification Database; 2011. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103626.pdf. Accessed October 24, 2011
- Light Age Inc. 510(k) Summary K110370. Q-Clear, Light Age [Internet]. FDA 510(k) Premarket Notification Database; 2011. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K110370.pdf. Accessed October 24, 2011
- Blueshine. 510(k) Summary K110375. GOLD, Blueshine. [Internet]. FDA 510(k) Premarket Notification Database; 2012. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K110375.pdf. Accessed 31 May, 2012
- Sciton Inc. 510(k) Summary K111483. JOULE ClearSense, Sciton Inc. [Internet]. FDA 510(k) Premarket Notification Database; 2011. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K111483.pdf. Accessed December 20, 2011
- Fotona Inc. 510(k) Summary K113702. XP Nd:YAG Laser System Family, Fotona Inc. [Internet]. FDA 510(k) Premarket Notification Database; 2012. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113702.pdf. Accessed 16 April, 2012
- Alma Lasers. 510(k) Summary K113810. Harmony, Alma Lasers Inc. [Internet]. FDA 510(k) Premarket Notification Database; 2012. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113810.pdf. Accessed March 19, 2012
- Lutronic Corporation. 510(k) Summary K113843. Freedom Laser System, Lutronic Corporation. [Internet]. FDA 510(k) Premarket Notification Database; 2012. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K113843.pdf. Accessed October 1, 2012
- Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother. 2006;4:1–13
- Sadighha A, Mohagheghzahed G. Onychomycosis: report on experience with itraconazole in 37 patients aged older than 50 years: a multivariate regression. Clin Exp Dermatol. 2009;34:924–5
- Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42:217–24